Genomic cancer testing identifies alterations within cells’ DNA that can give greater insight into a tumor’s function, information that can be used to match patients with approved or investigational treatments. However, according to the pharmaceuticals giant, only 25 percent of cancer patients and caregivers currently discuss genomic cancer testing with a physician.
“Genomic cancer testing allows physicians to create a more individualized treatment plan for the patient based on their cancer,” Robert LaCaze, EVP of Bayer’s Oncology Strategic Business Unit, said. “During this important time when innovation in cancer treatment is rapidly evolving, Bayer is encouraging genomic cancer testing from the start of a diagnosis, in order to make well-informed treatment decisions based on the patient’s cancer.”
More articles about health IT:
Scientists use CRISPR gene editing as antidote to box jellyfish stings
Avoid the ‘basic cardinal sins of password generation’: 3 questions with UC Davis security expert Dr. Jeff Tully
Cerner’s chief people officer to retire in June
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.